Evidence map›Paper›PMID 40786749›Full record

ArticleInternational journal of chronic obstructive pulmonary disease2025

Breath and Bottle: Evaluating Pharmacotherapy for Alcohol Use Disorder on COPD Exacerbation Outcomes.

Teng Zhang, Qin Ding, Mengmeng Liu, Yanning Song, Lvfeng Zhang, Na Liang, Xia Zhao, Qian Wang, Xueli Guo, Guangmei Yang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of chronic obstructive pulmonary disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Teng Zhang *The Affiliated Encephalopathy Hospital of Zhengzhou University, Zhumadian, People's Republic of China.
Qin Ding *Nutritional Department, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China.
Mengmeng LiuThe Affiliated Encephalopathy Hospital of Zhengzhou University, Zhumadian, People's Republic of China.
Yanning SongThe Affiliated Encephalopathy Hospital of Zhengzhou University, Zhumadian, People's Republic of China.ORCID 0000-0002-4263-2271
Lvfeng ZhangThe Affiliated Encephalopathy Hospital of Zhengzhou University, Zhumadian, People's Republic of China.
Na LiangThe Affiliated Encephalopathy Hospital of Zhengzhou University, Zhumadian, People's Republic of China.
Xia ZhaoThe Affiliated Encephalopathy Hospital of Zhengzhou University, Zhumadian, People's Republic of China.
Qian WangThe Affiliated Encephalopathy Hospital of Zhengzhou University, Zhumadian, People's Republic of China.
Xueli GuoThe Affiliated Encephalopathy Hospital of Zhengzhou University, Zhumadian, People's Republic of China.
Guangmei YangThe Affiliated Encephalopathy Hospital of Zhengzhou University, Zhumadian, People's Republic of China.
Hongwei ZhangThe Affiliated Encephalopathy Hospital of Zhengzhou University, Zhumadian, People's Republic of China.
Wei ChenNutritional Department, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The role of pharmacotherapy for alcohol use disorder (AUD) in mitigating COPD exacerbations remains underexplored. This study aims to evaluate the impact of AUD pharmacotherapy on COPD-related clinical outcomes. Methods: A retrospective cohort study was conducted on 635 COPD patients with comorbid AUD. Patients were categorized into two groups based on whether they received medication for AUD (MAUD group) or not (no-MAUD group). Data on demographics, COPD severity, exacerbation rates, and AUD treatment were extracted from electronic medical records. Results: Individuals in the MAUD group (n=229) exhibited a substantially reduced frequency of COPD exacerbations when compared to those in the non-MAUD group (n=406), with a significant difference observed ( Conclusion: Pharmacotherapy for AUD appears to have a protective effect against the occurrence of COPD exacerbations and improved clinical outcomes in patients with comorbid AUD. These findings suggest that AUD treatment should be considered as part of a comprehensive management strategy for COPD patients with AUD.

Indexed as

Alcohol DeterrentsAlcoholismLungPulmonary Disease, Chronic ObstructiveAgedComorbidityDisease ProgressionFemaleHumansMaleMiddle AgedRetrospective StudiesRisk FactorsSeverity of Illness IndexTime FactorsTreatment OutcomeAlcohol Deterrentsaddiction treatmentalcohol use disorderchronic obstructive pulmonary diseaseexacerbation

Identifiers

PMID40786749
PMCPMC12333649

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.